The slogan we adopted for the TTS 2022 Congress is "Committed to Access and Transparency" and as a lead-up to the Congress we have launched a new needs assessment survey which will aid TTS in developing new programs, educational material and strategies to better improve access and transparency in the field of transplantation. As a non-governmental organization in official relations with the World Health Organization (WHO) the information collected will feed into the work TTS is doing as part of our WHO collaboration.
Your support, by completing this survey, will contribute to the success of this initiative. Your answers will be kept confidential and anonymous.
In this issue you will find collected together all of the information that we needed in March 2020 on the impact of COVID-19, the effectiveness of vaccination and the treatments needed to reduce the terrible early mortality we witnessed in our transplant populations. Proving that COVID has not stopped scientific discovery we also have some great articles on biomarkers, kidney biopsy and diagnosis of cardiac rejection. There is a really neat report on immunoproteomics in heart recipients and a study that highlights the unintended consequences of imflifidase treatment on analysis of HLA antibodies. Much to keep you busy reading as you head for a summer break
CLICK HERE TO ACCESS THIS ISSUE
TTS MEMBERS - CLICK HERE TO SIGN-IN FOR OPEN ACCESS THROUGH TTS.ORG
DSA Are Associated With More Graft Injury, More Fibrosis, and Upregulation of Rejection-associated Transcripts in Subclinical Rejection #TBT bit.ly/3a9cRsa
Subclinical T cell-mediated rejection (subTCMR) is commonly found after liver transplantation and has a good short-term prognosis, even when it is left untreated. Donor-specific antibodies (DSA) are putatively associated with a worse prognosis for recipient and graft after liver transplantation.Textbook Outcome as a Quality Metric in Liver Transplantation #OpenAccess #liver #TransplantTwitter bit.ly/3mlsipm
Quality in liver transplantation (LT) is currently measured using 1-y patient and graft survival. Because patient and graft survival rates now exceed 90%, more informative metrics are needed. Textbook outcomes (TOs) describe ideal patient outcomes after surgery. This study critically evaluates TO as a quality metric in LT.With the advent of John Fung (USA) being elected as TTS President-Elect (2022-2024), the Vice President position (2022-2026) will be vacated at the end of the TTS 2022 Congress. This by-election is being held to fill this new vacancy.
Minnie Sarwal is a pediatric and adult transplant nephrologist who has worked in the field of transplantation since 1997. She has trained and worked in 3 continents (Asia, Europe and North America), and is passionate about improving outcomes after organ transplantation for both children and adult transplant recipients, globally. She has dedicated her career to advancing mechanisms and management of transplant rejection by innovations in immunosuppression design and diagnostic biomarkers, and directs an NIH-funded Precision Transplant Lab and has authored over 300 peer reviewed publications. She has been an elected IPTA Councilor (2006), IPTA Outreach Committee Chair (2010-2015), TTS KOL (2008-2012), elected TTS Councilor (2014-2018), TTS Junior Treasurer (2018-2020) and TTS Senior Treasurer (2020-2022). She founded the TTS-Transplantomics meeting (2010-15) and advises the FDA Commissioner on the FDA Science Board (2017- 2022). She is currently a Professor in Residence, Department of Surgery, the Medical Director of the Kidney-Pancreas Transplant Program and Co-Director of the T32 Training Grant in Transplant Surgery, at the University of California San Francisco (UCSF). She has previously been Professor, Pediatrics and Surgery, and Medical Director of the Pediatric Kidney Transplant Program at Stanford University where she developed the first complete steroid avoidance program for renal transplantation in infants and children. A prolific speaker and educator, Minnie holds the TTS-Roche Award for Outstanding Achievement in Transplantation Science (2010), National Kidney Foundation- Cuneo Richardson Award for Excellence in Research (2012), is a Capstone Mentor for the Berkeley-Haas Masters in Translational Medicine (MTM; 2015-2022) and is Chief Editor, Frontiers in Nephrology (Nature). Her vision for TTS is to improve outreach, alliances and advances in technology and diagnostics globally and to developing countries to improve outcomes and equity in transplantation.
Stefan G. Tullius, MD, PhD, FACS, is the Joseph E. Murray, MD Distinguished Chair in Transplant Surgery, Professor of Surgery, Harvard Medical School. He has roots in both Europe and the USA, and collaborations around the world. After training in Berlin, he was appointed Chief of Transplant Surgery and Director of the Transplant Surgery Research Lab at Brigham & Women’s Hospital, Boston, in 2005. Dr. Tullius has served as Councilor and Treasurer for TTS and has been on the Boards of ESOT and UNOS. He is currently a Board member of the National Kidney Registry and Vice President of the Int’l Society of Uterus Transplantation, now a section of TTS. He is an Executive Editor, Transplantation, a position he has held since 2014. He is also an Associate Editor of Transplant International (since 2004), the Korean Journal of Transplantation, and has been an Associate Editor for AJT. In addition to being an active transplant surgeon, Dr. Tullius runs a prolific NIHfunded laboratory. His international collaborations include institutions in China, India, Argentina, Japan and Germany. Dr. Tullius is proud of his many clinical and research mentees who have moved on with their own successful clinical and research careers. His own work has been recognized with several awards including the Clinical Science Investigator Award of the AST, Excellence in Transplantation Award by the National Kidney Foundation, and the Outstanding Ach ievement Award by TTS. Dr. Tullius looks forward to serving TTS advancing the society’s international clinical, scientific, and ethical mission.
The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada